NEJM officially publishes preliminary results of the Redsey wee global trial, significantly reducing recovery time

Three redwest clinical trials were released almost simultaneously in late AprilChina's randomized double-blind trial ended prematurely, data failed to show benefits for patients with severe neo-coronavirus disease (COVID-19), Redsiewe significantly accelerated recovery times in hospitalized patients with new coronary pneumonia in clinical trials sponsored by the American Institute of Allergy and Infectious Diseases (NIAID), and Gilead Sciences announced that the SIMPLE Phase 3 trial, the Redsiewe 5-day and 10-day treatment programs were similar to those with severe efficacyMay 22, local time, NIAID sponsored the preliminary report of the global randomized double-blind trial, called ACTT-1, was officially published in the New England Journal of Medicine, bringing more detailed results and data updates than previous lying announcements, still supporting Redcywe's significantly reduced recovery time for COVID-19 hospitalized adult patients and the potential benefits of improving the risk of deathscreenshot source: New England Journal of MedicineThe trial is an adaptively designed, randomized double-blind, placebo-controlled, worldwide Phase 3 clinical trialThe trial began on 21 February 2020 and ended on 19 April 2020A total of 73 clinical centers are in the United States, Denmark, the United Kingdom, Greece, Germany, South Korea, Mexico, Spain, Japan and Singaporegroup of patients were hospitalized with COVID-19 confirmed by nucleic acid testing and showed signs of lower respiratory tract infectionThe patients were randomly grouped, with the Redsiewe group receiving a 10-day treatment, with a first-day dose of 200 mg, followed by 100 mg, once a dayThe control group received a matching placeboAll patients received supportive treatment according to the standards of their hospital1063 patients were subjected to randomized groupingsThe average age of these patients was 58.9 years, compared with 64.3 per cent for menWhites accounted for 53.2 per cent, blacks 20.6 per cent, Asians 12.6 per cent and other or unreported 13.6 per centThe median time between the onset of the patient and the random group treatment was 9 days, and 943 patients were severely illPreliminary results were from 1,059 patients with available data (538 in the Redsywe group and 521 in the placebo group)The main endpoint of the test for the mapping of the drug Mingkangde content team was the time it took for patients to recover within 29 days of treatment The analysis showed that patients treated with Rhedciere recovered 32 percent faster Specifically, the median recovery time was 11 days in patients in the Redcywe treatment group, compared with 15 days in the placebo group the team observed that the effects of patients receiving Redciewe treatment varied according to the severity of the disease before the trial: patients who did not need oxygen absorption before the trial but needed continuous medical care (127 cases), Redsiewe recovered 38% faster ; patients who already required mechanical ventilation or ECMO before the trial (272 cases), the Redsiewe group did not significantly accelerate recovery however, statistics found that the effect of baseline disease on treatment was not significant The team suggested that the finding was most likely due to the largest number of patients who needed to be hospitalized to absorb oxygen prior to hospitalization Patients who late to the drug seem edbetter Reedsiwe recovery was 28% faster in the first 10 days of the disease and 38% faster after 10 days of illness also showed an advantage in the secondary end On the 15th day, patients in the Redsywe group had a 50 percent higher chance of improving symptoms The data also suggest that Redsiewe may have a survival benefit, with the redsiewe and placebo groups estimating that the mortality rate was 7.1% and 11.9% on the 14th day, respectively, and that the risk of dystow was reduced by 30% but not significant safety, 114 (21.1%) of the Redsywe group had severe adverse events and the placebo group had 141 (27.0%) There were 28 cases of severe respiratory failure (5.2% of patients) in the Redsywe group and 42 cases (8.0% of patients) in the placebo group In the placebo group, acute respiratory failure, hypotension, viral pneumonia, and acute kidney injury were more common in patients According to the researchers, no patient deaths were associated with experimental treatment drug Mingconde Content team mapping as of data analysis, the treatment is still a large number of patients have not recovered in 29 days, still in follow-up The research team also indicated that more indicator analysis will be conducted after the follow-up, which may lead to more insights from the sub-group the team also suggested the difference between the study and clinical trials in China, where only 237 patients were included in the 2:1 group of trial groups and placebo groups due to early termination, while the ACTT-1 trial was larger and 1:1 randomized, and the data were likely to be more statistically effective overall, the team believes these preliminary findings support Redcywe's use of patients who need coVID-19 hospitalization and need oxygen absorption But given the high risk of death from the disease, antiviral therapy alone is not enough, future treatment strategies may assess the effectiveness of combined applications with other treatments.